Abbott Acquires Remaining Rights to Trandolapril from Aventis
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 49 (Table of Contents)
Published: 4 Jul-2004
DOI: 10.3833/pdr.v2004.i49.801 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Abbott Laboratories acquired the remaining manufacturing and marketing rights to trandolapril and its combination drug verapamil from Aventis for a total payment of US$300 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
Login Problems
RSS